Proactive’s Tylah Tully has JustTheFacts on why Argent BioPharma Ltd (LSE:MXC, OTC:RGTLF, ASX:RGT)’s shares rose as much as 64.71% to $0.42 per share in trading today.
The company entered a strategic collaboration with SINTEF, one of Europe’s largest independent research organisations, to tackle the critical clinical challenge of chronic wound care.
Chronic wounds pose a major public health issue, inflicting severe suffering on patients and affecting large numbers of people around the world.
The cost of managing poorly healing wounds is estimated at around US$250 billion every year